关注
Sarra Mestiri
Sarra Mestiri
Qatar Biomedical Research Institute (QBRI)
在 hbku.edu.qa 的电子邮件经过验证
标题
引用次数
引用次数
年份
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Q Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, ...
Annals of medicine 54 (1), 524-540, 2022
3722022
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
KM Maalej, M Merhi, VP Inchakalody, S Mestiri, M Alam, C Maccalli, ...
Molecular Cancer 22 (1), 20, 2023
1212023
Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer
A Raza, AQ Khan, VP Inchakalody, S Mestiri, ZSKM Yoosuf, T Bedhiafi, ...
Journal of Experimental & Clinical Cancer Research 41 (1), 99, 2022
592022
The potential role of vitamin C in empowering cancer immunotherapy
T Bedhiafi, VP Inchakalody, Q Fernandes, S Mestiri, N Billa, S Uddin, ...
Biomedicine & Pharmacotherapy 146, 112553, 2022
402022
The role of PAK4 in the immune system and its potential implication in cancer immunotherapy
A Naїja, M Merhi, V Inchakalody, Q Fernandes, S Mestiri, KS Prabhu, ...
Cellular Immunology 367, 104408, 2021
202021
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy …
M Merhi, A Raza, VP Inchakalody, KS Siveen, D Kumar, F Sahir, S Mestiri, ...
Journal for Immunotherapy of Cancer 8 (2), 2020
132020
Chronic inflammation and cancer; the two sides of a coin
Q Fernandes, VP Inchakalody, T Bedhiafi, S Mestiri, N Taib, S Uddin, ...
Life Sciences, 122390, 2023
82023
The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling
E Laplantine, C Chable-Bessia, A Oudin, J Swain, A Soria, P Merida, ...
Iscience 25 (10), 2022
82022
The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target
L Al-Zaidan, S Mestiri, A Raza, M Merhi, VP Inchakalody, Q Fernandes, ...
Tumor Biology 43 (1), 177-196, 2021
72021
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines., 2022, 54
Q Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, DMA El-Ella, ...
DOI: https://doi. org/10.1080/07853890.2022 2031274, 524-540, 0
7
Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
N Taib, M Merhi, V Inchakalody, S Mestiri, S Hydrose, K Makni-Maalej, ...
Journal of translational medicine 21 (1), 235, 2023
62023
The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
S Mestiri, DMA El-Ella, Q Fernandes, T Bedhiafi, S Almoghrabi, S Akbar, ...
Biomedicine & Pharmacotherapy 171, 116095, 2024
22024
The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR)
VP Inchakalody, SP Hydrose, R Krishnankutty, M Merhi, L Therachiyil, ...
European Journal of Pharmacology 945, 175612, 2023
22023
Vaccines and Immunotherapies against the Human Papillomavirus and Epstein-Barr Virus
Q Fernandes, S Mestiri, T Bedhiafi, A Raza, M Merhi, S Hydrose, ...
Advances in Health and Disease 60, 2022
12022
SARS-CoV-2 S protein binding hACE2: viral entry, pathogenesis, prognosis, and potential therapeutic targets
L Al-Zaidan, S Mestiri, A Raza, M Merhi, V Inchakalody, Q Fernandez, ...
Preprints, 2020
12020
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive …
S Mestiri, M Merhi, VP Inchakalody, N Taib, MK Smatti, F Ahmad, A Raza, ...
Frontiers in Immunology 14, 1061255, 2023
2023
Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives
F Al-Ejeh, M Merhi, M Al-Muftah, Q Fernandes, L Al-Zaidan, T Bedhiafi, ...
Omics approaches and technologies in COVID-19, 61-85, 2023
2023
736 Treatment with decitabine (DAC) induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer
N Taib, M Merhi, V Inchakalody, S Mestiri, A Raza, S Uddin, C Maccalli, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A767-A767, 2021
2021
463 Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno …
M Merhi, A Raza, V Inchakalody, S Kodappully, D Choubey, F Sahir, ...
Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020
2020
Identification of a Novel Promiscuous Anti-NY-ESO-1 Immunogenic CD4+ Peptide Containing a CD8+ T-Cell Epitope Highly Present in Metastatic Gastric Cancer Responding to Combined …
M Merhi, A Raza, V Inchakalody, S Sivaraman, F Panayampilly, S Mestiri, ...
Annals of Oncology 30, xi41, 2019
2019
系统目前无法执行此操作,请稍后再试。
文章 1–20